Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junya Kanda

Showing results (371-380 of 390) with videos related to

Pageof 39
Sort By:
Leukemia|January 7, 2026
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partnersKazuhisa Chonabayashi, Makoto Iwasaki, Junya Kanda, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Blood Advances|April 17, 2026
Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignanciesMari Morita-Fujita, Shuji Kawaguchi, Takero Shindo, et al.
Transplantation and Cellular Therapy|March 8, 2023
Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic MalignancyMari Morita-Fujita, Takero Shindo, Tomoki Iemura, et al.
European Journal of Haematology|September 9, 2025
Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid LeukemiaChika Tokuda, Makoto Iwasaki, Junya Kanda, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Blood Advances|October 21, 2018
Prognostic impact of low allelic ratio <i>FLT3-</i>ITD and <i>NPM1</i> mutation in acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 7, 2018
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free SurvivalAmin Alousi, Tao Wang, Michael T Hemmer, et al.
Pageof 39

Showing results (371-380 of 390) with videos related to

Sort By:
Pageof 39
Leukemia|January 7, 2026
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partnersKazuhisa Chonabayashi, Makoto Iwasaki, Junya Kanda, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Blood Advances|April 17, 2026
Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignanciesMari Morita-Fujita, Shuji Kawaguchi, Takero Shindo, et al.
Transplantation and Cellular Therapy|March 8, 2023
Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic MalignancyMari Morita-Fujita, Takero Shindo, Tomoki Iemura, et al.
European Journal of Haematology|September 9, 2025
Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid LeukemiaChika Tokuda, Makoto Iwasaki, Junya Kanda, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Blood Advances|October 21, 2018
Prognostic impact of low allelic ratio <i>FLT3-</i>ITD and <i>NPM1</i> mutation in acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 7, 2018
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free SurvivalAmin Alousi, Tao Wang, Michael T Hemmer, et al.
Pageof 39